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Background: We investigated the efficacy and safety of AZD3199, a novel inhaled ultra-LABA, with the main aim of
establishing a dose that would maintain 24-hour bronchodilation in patients with COPD.
Methods: Patients (n = 329) were randomized to AZD3199 (200, 400 or 800 μg o.d.), formoterol (9 μg b.i.d.) or
placebo via Turbuhaler® in a parallel group study. The primary objective of the study was to compare the clinical
efficacy of three doses of AZD3199 inhaled once daily with 9 μg formoterol twice daily and placebo, over a 4-week
treatment period in adults with moderate-to-severe COPD. After 4 weeks, peak (0–4 h) and trough (24–26 h) forced
expiratory volume in 1 second (FEV1) were assessed as the primary efficacy outcome variables.
Results: All AZD3199 doses significantly increased mean peak and trough FEV1 versus placebo (106–171 ml and
97–110 ml increases, respectively), but with no clear dose–response; the level of bronchodilation was comparable
to or greater than that achieved with formoterol. Forced vital capacity (FVC) at peak bronchodilation also
significantly increased with AZD3199 versus placebo (153–204 ml). COPD symptom scores and reliever use were
reduced with AZD3199, while FEV1 reversibility was unaltered. Adverse events were mild-to-moderate, with no
safety concerns identified. Drug exposure was dose-proportional, but lower than predicted from healthy volunteers.
Conclusions: All three doses of AZD3199 produced 24-hour bronchodilation, but with no clear dose–response,
suggesting that doses of 200 μg or less may be sufficient to maintain bronchodilation over 24 hours in patients
with COPD. No safety concerns were identified. Further studies are required to determine the once-daily AZD3199
dose for COPD.
Trial registration: Clinicaltrials.gov, NCT00929708
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by the progressive development of airway ob-
struction and airflow limitation. The condition is not
fully reversible and typically leads to a decline in exer-
cise performance and a deterioration in health [1].
COPD is associated with considerable morbidity and
mortality, posing an enormous burden to the health
care system [1,2]. Despite a decrease in the prevalence
of smoking in developed countries, it is predicted that* Correspondence: piotr.kuna@umed.lodz.pl
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reproduction in any medium, provided the orCOPD will be the third leading cause of death world-
wide by 2020 [3-5].
Symptomatic treatment with bronchodilators is re-
commended as the first stage of therapy for COPD [6].
As the symptoms of COPD require continual treatment,
long-acting bronchodilators are more convenient for the
patient and more effective on a number of endpoints
than short-acting alternatives. Current guidelines for the
treatment of COPD recommend a stepwise approach to
treatment, with bronchodilators central to symptomatic
management [6,7]. Regular use of long-acting β-agonists
(LABA) and long-acting muscarinic antagonists (LAMA),
either as monotherapy or in combination, is recom-
mended to achieve optimal bronchodilation and improve
health status [6-8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(uLABA, i.e. ≥ 24-hour duration of action) that has been
investigated in asthma and COPD. A Phase II trial in
patients with asthma (NCT00736489) demonstrated
AZD3199 to be a potent LABA, with a bronchodilatory
effect that persisted over 24 hours (data on file). The
aim of the present study was to compare the efficacy of
three different doses of inhaled, once-daily AZD3199
with that of twice-daily formoterol 9 μg in patients with
moderate to severe COPD. This study was conducted to
establish an appropriate dose of AZD3199 to be used
once-daily in patients with COPD.
Methods
Study design and medications
The trial was a 4-week randomized, double-blind,
placebo-controlled, parallel-group study conducted at 53
sites in Bulgaria, Canada, Japan, Poland and Russia. Pa-
tients with moderate-to-severe COPD who were symp-
tomatic during a 2-week run-in period (total COPD
symptom score ≥2 for at least half the number of days of
the run-in period) were randomized to treatment.
Patients who fulfilled the inclusion criteria and none
of the exclusion criteria entered the 2-week run-in
period with salbutamol as reliever medication (and in-
haled glucocorticosteroids [GCS] at a constant dose, if
applicable) as the only allowed COPD medications. Pa-
tients using an inhaled GCS combination product at
entry were switched to the corresponding monoproduct.
Patients had to have been treated with inhaled GCS for
at least 30 days before study entry to be allowed to con-
tinue monotherapy during the study.
At the end of the 2-week run-in period, patients were
randomized to receive AZD3199 (200 μg, 400 μg or 800 μg
once-daily), formoterol (9 μg twice-daily) or placebo,






















Figure 1 Patient flow.short-acting β2-agonist (salbutamol) could be used as
reliever medication.
Objectives, assessments and outcome measures
The primary objective of the study was to assess the effi-
cacy of AZD3199 in patients with COPD. The primary
variables were mean peak (0–4 hours post-drug adminis-
tration, E0-4) and mean trough (24–26 hours post-drug
administration, E24-26) forced expiratory volume in one
second (FEV1) following morning administration after 4
weeks of treatment. Spirometry measurements were
made pre-dose and then post-dose at 5 and 15 minutes
and then at 1, 2, 4, 24 and 26 hours.
Forced vital capacity (FVC) (E0–4 and E24–26), patient-
reported outcomes (AstraZeneca COPD symptom
scores, Clinical COPD Questionnaire [CCQ], St George’s
Respiratory Questionnaire for COPD [SGRQ-C]) and
morning and evening use of reliever medication were
assessed as secondary outcomes of the primary objective.
AstraZeneca COPD symptom scores were assessed on
a 5-point Likert-type scale and graded in severity from
0–4 [9]. The CCQ includes 10 questions summarized as
overall mean and in three domains; Symptoms (four
questions), Functional State (four questions) and Mental
State (two questions). Responses were assessed on a
7-point scale from 0–6. A decrease in score of 0.4 units
is regarded as the Minimal Important Difference (MID).
In the SGRQ-C, each domain (symptoms, activity and
impact) is scored individually and the domains are cal-
culated by weighing the questions. Scores range from
0–100, with a change in 4 percentage units or more
regarded as the MID.
The secondary objectives of the study were to investi-
gate the safety of AZD3199 and to assess drug exposure
of AZD3199. Safety variables included an examination of
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clinical chemistry and urinalysis). FEV1 reversibility was
also examined at randomization and at 26 hours after
the last morning dose of AZD3199 treatment; FEV1 was
assessed before and 15–30 minutes after inhalation of
salbutamol 400 μg. After 4 weeks of treatment, blood
samples were taken for analysis of AZD3199 pharmaco-
kinetics at steady state. The maximum plasma concen-
tration of AZD3199 (Cmax), time to Cmax (tmax) and the
area under the plasma concentration-time curve from
0–24 hours (AUC0–24) were examined.
Patients
To be eligible for the study, patients were required to
be aged 40 years or above, to be symptomatic, to have
a reproducible pre-bronchodilator FEV1 and with a
diagnosis of moderate-to-severe COPD for a period of
more than one year. Patients were required to have a
post-bronchodilator FEV1 value between 40 and 80%
of the predicted normal, and a post-bronchodilator
FEV1/ FVC ratio of less than 70%. Patients were to be
current or ex-smokers with a smoking history of at
least 10 pack-years.
Exclusion criteria for the study included current
asthma, a history of asthma or atopy (such as allergic
rhinitis) before 40 years of age. Patients with any current
respiratory tract disorder other than COPD, including
respiratory diseases described in GOLD 2008 or JRS
Guidelines 2004 as needing to be differentiated from
COPD, which was considered by the investigator to be
clinically significant were not included in the study.
Patients with a body mass index of less than 18 kg/m2
or a body weight of less than 30 kg were excluded from
the study, with pregnancy, lactation and past or present
alcohol or drug abuse as additional criteria for exclusion.
Patients with COPD exacerbations (defined as use of
systemic antibiotics and/or systemic glucocorticosteroids
and/or hospitalization related to COPD) in the previous
30 days, patients requiring regular oxygen use and pa-
tients with a heart condition affecting the QT/QTc inter-
val were also excluded from study participation.
Statistical methods
The sample size calculation was based on repeated FEV1
assessments after 4 weeks of treatment, with peak and
trough FEV1 as the primary endpoints. The pre-
bronchodilator FEV1 value at the start of the treatment
period constituted the baseline measurement. With 60
patients per group and a two-sided test at a 5% signifi-
cance level, there was an 80% chance to detect a true
difference of 5% between any two treatments. The sta-
tistical analyses were performed using SAS version 9.1.
Efficacy variables were compared between treatments
using analysis of variance models with treatment andcountry as fixed factors and baseline as a covariate. All
analysis models were additive. Pairwise treatment con-
trasts were calculated including estimated mean dif-
ferences with 95% confidence intervals and p-values.
Pharmacokinetic parameters were summarized using de-
scriptive statistics for each dose level. A closed test pro-
cedure starting with the highest dose of AZD3199 was
used when determining the efficacy of AZD3199 relative
to placebo.
Ethics
The clinical study protocol was approved in writing by the
independent ethics committee in each participating coun-
try. The study was performed in accordance with the eth-
ical principles that have their origin in the Declaration of
Helsinki and that are consistent with International Con-
ference on Harmonisation (ICH)/Good Clinical Practice
(GCP) and applicable regulatory requirements and the
AstraZeneca policy on Bioethics. Informed consent was
obtained from all patients prior to initiation of any study
specific procedures, with information about the study pro-
vided to all patients at visit 1.
Results
Baseline characteristics
Of the 490 patients enrolled in the study, 329 were ran-
domized to treatment. Incorrect enrolment (patients not
fulfilling inclusion/exclusion criteria) and voluntary dis-
continuation were the primary reasons for withdrawal
before randomization. The baseline characteristics of pa-
tients in each treatment arm were well-balanced and are
outlined in Table 1. The average patient age was 64.1
years (range: 40–92); 75% of subjects were male; 76%
were white and 24% were Asian. Participants were
former (47%) or current (53%) smokers, with a median
time since COPD diagnosis of 4 years (range: 0–29). The
average post-bronchodilator FEV1 was 61% (range: 40–80)
of predicted normal. Prior to enrolment inhaled corti-
costeroids were used by 59% of patients, with 44% of
patients using LABAs, 20% using LAMAs, 63% using
SABAs, 19% using SAMAs and 18% using other COPD
medications, such as tolubuterol, xanthines and muco-
lytics. Patients were withdrawn from LABA and LAMA
treatments following study enrolment. Inhaled salbuta-
mol was permitted during the study period as reliever
medication and patients who had been treated with
inhaled corticosteroids (ICS) for > 30 days prior to en-
rolment continued to take them at a constant dose
throughout the study.
Following randomization, 22 patients discontinued
the study, primarily due to exacerbations of COPD,
which fulfilled protocol-specific withdrawal criteria
(n = 7). Additional reasons for patient withdrawal included
incorrect enrolment (n = 5), voluntary discontinuation
Table 1 Patient characteristics
AZD3199 AZD3199 AZD3199 Formoterol Placebo
200 μg od (n = 65) 400 μg od (n = 69) 800 μg od (n = 65) 9 μg bid (n = 67) (n = 63)
Gender (%)
Male 47 (72.3) 53 (76.8) 45 (69.2) 51 (76.1) 51 (81.0)
Female 18 (27.7) 16 (23.2) 20 (30.8) 16 (23.9) 12 (19.0)
Age (years) 62.4 (45–81) 63.8 (40–82) 65.3 (41–92) 64.1 (47–77) 64.8 (46–84)
Race (%)
White 49 (75.4) 53 (76.8) 48 (73.8) 51 (76.1) 48 (76.2)
Asian 16 (24.6) 16 (23.2) 17 (26.2) 16 (23.9) 15 (23.8)
BMI (kg/m2) 26.6 (18–41) 25.3 (18–35) 25.3 (18–47) 25.4 (18–36) 25.7 (19–38)
Time since COPD diagnosis (years)a 4.1 (0–19) 3.1 (0–29) 3 (0–18) 4.1 (0–24) 3.5 (0–17)
Smoking status (%)
Ex-smoker 34 (52.3) 32 (46.4) 27 (41.5) 36 (53.7) 27 (42.9)
Current 31 (47.7) 37 (53.6) 38 (58.5) 31 (46.3) 36 (57.1)
Pack-years (years) 36 (10–145) 41 (10–156) 46 (10–126) 39 (10–123) 40 (10–140)
Total COPD symptom score 6.0 (2–12) 5.8 (2–12) 6.0 (1–12) 5.8 (1–14) 5.7 (0–11)
FEV1 (% predicted normal)
b 60.1 (41.4–79.8) 63.1 (39.7–79.6) 60.6 (40.4–79.9) 60.9 (40.4–79.9) 61.3 (41.7–78.5)
Reversibility (%) 7.4 (−11.0–27.9) 11.9 (−12.4–74.4) 10.1 (−14.1–29.6) 9.4 (−17.1–44.8) 6.8 (−7.7–51.0)
FEV1/FVC (%)
b 55.2 (30.9–69.9) 56.1 (28.5–70.0) 52.4 (28.6–69.9) 54.6 (31.9–72.3) 56.1 (33.1–69.0)
ICS use (%)c 33 (50.8) 42 (60.9) 37 (56.9) 44 (65.7) 37 (58.7)
ICS dosec (μg) 737.6 (320–1000) 638.1 (200–1000) 620.5 (320–2000) 649.3 (200–1500) 671.1 (250–1000)
LAMA use (%)d 10 (15.4) 11 (15.9) 19 (29.2) 11 (16.4) 16 (25.4)
LABA use (%)e 29 (44.6) 30 (43.5) 29 (44.6) 28 (41.8) 28 (44.4)
SAMA use (%)f 14 (21.5) 16 (23.2) 9 (13.8) 9 (13.4) 14 (22.2)
SABA use (%)g 41 (63.1) 44 (63.8) 40 (61.5) 41 (61.2) 41 (65.1)
Other COPD medicationh 13 (20.0) 10 (14.5) 10 (15.4) 15 (22.4) 10 (15.9)
a Median; b Post-bronchodilator; c Inhaled corticosteroids; d Long-acting muscarinic antagonist; e Long acting β2-agonist;
f Short-acting muscarinic antagonist;
g Short-acting β2-agonist;
h Includes tolubuterol, xanthines and mucolytics.
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non-compliance to protocol (n = 1), with one patient lost to
follow-up.
Objectives, assessments and outcome measures
Peak and trough FEV1
After 4 weeks of treatment, all doses of AZD3199 had
increased mean peak and trough FEV1 values compared
with placebo, but no clear dose–response was observed
(Figure 2); peak FEV1 increased by 106–171 ml with
AZD3199 treatment compared with placebo, while
trough FEV1 increased by 97–110 ml (statistically signifi-
cant at all dose levels).
Formoterol 9 μg twice-daily treatment statistically sig-
nificantly increased peak FEV1 (114 ml increase) but not
trough FEV1 (18 ml increase).
All doses of once-daily AZD3199 had a comparable ef-
fect to formoterol 9 μg twice-daily with regards to peak
FEV1. On trough FEV1 there was a tendency towards in-
creased bronchodilation for all doses of AZD3199 versusformoterol 9 μg twice-daily (79–93 ml increase), but no
statistically significant differences were observed (p > 0.05)
(Table 2).FVC
In a similar manner to FEV1, peak FVC was statistically
significantly increased with all doses of AZD3199 com-
pared with placebo, but no clear dose–response was ob-
served (153–204 ml increase). Trough FVC was
increased by 86–184 ml with AZD3199 compared with
placebo, but the difference was not statistically signifi-
cant for AZD3199 200 μg or 800 μg.
Both peak and trough FVC were increased following
treatment with formoterol 9 μg twice-daily (168 ml and
30 ml respectively), but this only reached statistical sig-
nificance for peak FVC (p = 0.02).
There was no statistically significant difference in peak



























Time after morning administration (hours)
210 264 24
AZD3199 400 µg od
AZD3199 800 µg od
AZD3199 200 µg od
Formoterol 9 µg bid
Placebo
Figure 2 Adjusted mean changes in FEV1 after 4 weeks of treatment. Values shown are FEV1 changes (from baseline [day 1] to end of week
4) at each post-dose time-point. od = once daily; bid = twice daily. The formoterol study group received additional study medication at 12 hours.
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Overall mean CCQ scores (Table 3) were statistically sig-
nificantly reduced in the AZD3199 800 μg and formoterol
9 μg twice-daily treatment groups, in comparison with
placebo (p = 0.016 and 0.018 respectively). When assessed
by sub-domain, AZD3199 800 μg statistically significantly
reduced scores for mental state (p = 0.016).
All doses of AZD3199 reduced COPD symptom scores,
and this reached statistical significance for AZD3199 800
μg in reducing total symptom score (p = 0.008) (Table 3)
and the individual symptom scores for breathlessness
(p = 0.016), chest tightness (p = 0.05) and night-time
awakenings (p = 0.003), in comparison with placebo.
Total symptom score and individual symptom score
were not significantly altered in the formoterol 9 μg
twice-daily treatment group versus placebo. In compa-
rison with formoterol 9 μg twice-daily, AZD3199 800 μg
also statistically significantly reduced total symptoms
(p = 0.033) and breathlessness (p = 0.007).
All active treatments reduced total SGRQ-C scores
versus placebo, with scores lowered by 2.03–5.59 units
with AZD3199 treatment (not statistically significant for
AZD3199 800 μg) and 2.33 units for formoterol 9 μg
twice-daily (Table 3). A decrease of 4 units is regarded
as the clinically relevant MID. Reductions in the sub-
domain scores for symptoms, activity and impact were
also observed. However, reductions in total and SGRQ
sub-domain scores did not reach statistical significance
for AZD3199 800 μg and formoterol 9 μg, in compari-
son with placebo.
All doses of AZD3199 statistically significantly reduced
the daily use of rescue medication in comparison with
the placebo group, with the greatest reduction in rescuemedication use after AZD3199 400 μg and 800 μg. In
contrast, formoterol 9 μg twice-daily did not statistically
significantly influence the daily use of rescue medication
when compared with placebo.
FEV1 reversibility
In all AZD3199 treatment groups, FEV1 measurements
post-salbutamol inhalation increased by approximately
50 ml over the course of the study. Numerically, but not
statistically, larger increases in post-salbutamol FEV1
values were observed for the AZD3199 treatment arms
than for the placebo and formoterol 9 μg treatment
arms. The increase in pre-salbutamol FEV1 was approxi-
mately 100 ml for all AZD3199 treatment groups,
resulting in a numerically smaller (5%) reversibility
compared with the groups receiving formoterol 9 μg
twice-daily or placebo. Thus, there were no adverse ef-
fects of AZD3199 on the acute bronchodilatory action
of salbutamol.
Safety
In the placebo group, one death was reported but this
was judged as not causally related to the study drug, and
was attributed to circulatory collapse. Serious adverse
events were evenly distributed between the treatment
groups. Overall, 8 patients experienced 10 serious ad-
verse events (AZD3199 200 μg, n = 1; AZD3199 400 μg,
n = 4; AZD3199 800 μg, n = 0; formoterol 9 μg, n = 3;
placebo, n = 2), of which 2 (both in the formoterol 9 μg
treatment group) were considered to be causally related
to the study medication. Discontinuation of treatment
due to adverse events (DAEs) was reported for 11 pa-
tients, primarily due to exacerbation of COPD. DAEs




Difference (ml) 95% CI P-value*
FEV1, E0–4 AZD3199 200 μg od 199.7 AZD3199 200 vs Placebo 171 69.2, 272.9 0.001
AZD3199 400 μg od 163.2 AZD3199 400 vs Placebo 135 34.7, 234.3 0.008
AZD3199 800 μg od 134.3 AZD3199 800 vs Placebo 106 4.6, 206.8 0.041
Formoterol 9 μg bid 142.8 Formoterol 9 vs Placebo 114 12.8, 215.6 0.027
Placebo 28.6 AZD3199 200 vs Formoterol 9 57 −42.7, 156.4 0.262
AZD3199 400 vs Formoterol 9 20 −77.4, 118.2 0.682
AZD3199 800 vs Formoterol 9 −8 −107.2, 90.3 0.866
FEV1, E24–26 AZD3199 200 μg od 104.1 AZD3199 200 vs Placebo 99 2.4, 194.9 0.045
AZD3199 400 μg od 115.9 AZD3199 400 vs Placebo 110 16.0, 204.7 0.022
AZD3199 800 μg od 102.1 AZD3199 800 vs Placebo 97 0.5, 192.5 0.049
Formoterol 9 μg bid 23.4 Formoterol 9 vs Placebo 18 −78.0, 113.7 0.714
Placebo 5.5 AZD3199 200 vs Formoterol 9 81 −13.4, 174.9 0.092
AZD3199 400 vs Formoterol 9 93 0.1, 185.0 0.050
AZD3199 800 vs Formoterol 9 79 −15.0, 172.4 0.100
FVC, E0–4 AZD3199 200 μg od 186.3 AZD3199 200 vs Placebo 192 50.2, 334.3 0.008
AZD3199 400 μg od 198.2 AZD3199 400 vs Placebo 204 64.9, 343.4 0.004
AZD3199 800 μg od 146.7 AZD3199 800 vs Placebo 153 11.7, 293.5 0.034
Formoterol 9 μg bid 162.1 Formoterol 9 vs Placebo 168 26.5, 309.5 0.020
Placebo −5.9 AZD3199 200 vs Formoterol 9 24 −114.7, 163.2 0.731
AZD3199 400 vs Formoterol 9 36 −100.0, 172.3 0.602
AZD3199 800 vs Formoterol 9 −15 −153.1, 122.3 0.826
FVC, E24–26 AZD3199 200 μg od 69.8 AZD3199 200 vs Placebo 86 −43.3, 214.9 0.192
AZD3199 400 μg od 167.9 AZD3199 400 vs Placebo 184 57.4, 310.5 0.005
AZD3199 800 μg od 97.9 AZD3199 800 vs Placebo 114 −14.7, 242.5 0.082
Formoterol 9 μg bid 13.5 Formoterol 9 vs Placebo 30 −99.1, 158.1 0.652
Placebo −16.0 AZD3199 200 vs Formoterol 9 56 −70.0, 182.6 0.381
AZD3199 400 vs Formoterol 9 155 30.7, 278.2 0.015
AZD3199 800 vs Formoterol 9 84 −41.2, 210.1 0.187
*Not adjusted for multiple comparisons.
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(AZD3199 200 μg, n = 0; AZD3199 400 μg, n = 2;
AZD3199 800 μg, n = 2; formoterol 9 μg, n = 3; placebo,
n = 4).
Altogether, 128 adverse events were experienced by 84
patients (26%). The majority of adverse events (95.3%)
were considered to be of mild or moderate intensity,
with nasopharyngitis, cough, COPD exacerbation and
throat irritation reported most frequently (Table 4). The
number of patients experiencing an adverse event was
highest in the group receiving AZD3199 400 μg and
lowest in the group receiving AZD3199 200 μg. The
higher incidence of adverse events in the AZD3199 400
μg treatment group was attributable to several patients
experiencing multiple events. Less than one-third (31.3%)of the total adverse events were considered to be causally
related to the study medication.
There were no consistent clinically significant changes
across treatment groups in blood pressure, pulse, ECG
or clinical laboratory parameters. As such, no safety con-
cerns were raised for AZD3199.
Pharmacokinetics
Analysis of Cmax and AUC0–24 for AZD3199 indicated
steady-state exposure to be dose-proportional (Table 5).
The exposure of AZD3199 was approximately half of that
previously observed in healthy volunteers and patients
with mild-to-moderate asthma. Absorption of AZD3199
was rapid, with a median tmax of 15 minutes for all doses
of AZD3199.




Difference 95% CI P-value*
CCQ variable
Overall mean AZD3199 200 μg od −0.38 AZD3199 200 vs Placebo −0.262 −0.457, -0.067 0.009
AZD3199 400 μg od −0.30 AZD3199 400 vs Placebo −0.178 −0.369, 0.014 0.068
AZD3199 800 μg od −0.36 AZD3199 800 vs Placebo −0.240 −0.435, -0.045 0.016
Formoterol 9 μg bid −0.36 Formoterol 9 vs Placebo −0.234 −0.427, -0.040 0.018
Placebo −0.12 AZD3199 200 vs Formoterol 9 −0.028 −0.219, 0.162 0.770
AZD3199 400 vs Formoterol 9 0.056 −0.132, 0.243 0.559
AZD3199 800 vs Formoterol 9 −0.007 −0.198, 0.184 0.945
AZ Diary card COPD Symptoms
Total Score (0–16) AZD3199 200 μg od −0.94 AZD3199 200 vs Placebo −0.480 −1.011, 0.051 0.076
AZD3199 400 μg od −0.94 AZD3199 400 vs Placebo −0.473 −1.000, 0.054 0.078
AZD3199 800 μg od −1.19 AZD3199 800 vs Placebo −0.723 −1.254, -0.192 0.008
Formoterol 9 μg bid −0.62 Formoterol 9 vs Placebo −0.152 −0.685, 0.380 0.574
Placebo −0.46 AZD3199 200 vs Formoterol 9 −0.327 −0.852, 0.197 0.220
AZD3199 400 vs Formoterol 9 −0.321 −0.841, 0.200 0.226
AZD3199 800 vs Formoterol 9 −0.570 −1.095, -0.046 0.033
SGRQ-C Scores
Total Score AZD3199 200 μg od −5.61 AZD3199 200 vs Placebo −3.01 −7.31, 1.28 0.169
AZD3199 400 μg od −8.18 AZD3199 400 vs Placebo −5.59 −9.78, -1.40 0.009
AZD3199 800 μg od −4.63 AZD3199 800 vs Placebo −2.03 −6.29, 2.23 0.350
Formoterol 9 μg bid −4.93 Formoterol 9 vs Placebo −2.33 −6.65, 1.99 0.289
Placebo −2.60 AZD3199 200 vs Formoterol 9 −0.68 −4.89, 3.53 0.751
AZD3199 400 vs Formoterol 9 −3.25 −7.34, 0.83 0.118
AZD3199 800 vs Formoterol 9 0.30 −3.86, 4.47 0.886
*Not adjusted for multiple comparisons.
AZ, AstraZeneca; CCQ, Clinical COPD Questionnaire; SGRQ-C, St George’s Respiratory Questionnaire for COPD.
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This is the first study to evaluate the efficacy and safety
of AZD3199 in patients with COPD. Treatment doses
were selected based on the results of a Phase IIa study
in patients with asthma (NCT00736489) and a multipleTable 4 Adverse events





Patients with any adverse event 8 (12.3) 21 (30.4)
Nasopharyngitis 1 (1.5) 4 (5.8)
Cough 0 (0.0) 4 (5.8)
Chronic obstructive pulmonary disease 1 (1.5) 2 (2.9)
Throat irritation 1 (1.5) 0 (0.0)
Bronchitis 0 (0.0) 0 (0.0)
Headache 0 (0.0) 2 (2.9)
Product taste abnormal 1 (1.5) 0 (0.0)ascending dose (MAD) study in healthy volunteers
(NCT00713271), where AZD3199 was administered via
Turbuhaler®. The low dose of 200 μg was selected based
on the Phase IIa study, as the lowest dose with a poten-
tial for 24-hour duration of action. To provide a 2-foldNumber (%) of patients
AZD3199 Formoterol Total






19 (29.2) 18 (26.9) 18 (28.6) 84 (25.5)
3 (4.6) 2 (3.0) 3 (4.8) 13 (4.0)
4 (6.2) 2 (3.0) 0 (0.0) 10 (3.0)
2 (3.1) 2 (3.0) 2 (3.2) 9 (2.7)
1 (1.5) 2 (3.0) 1 (1.6) 5 (1.5)
2 (3.1) 0 (0.0) 2 (3.2) 4 (1.2)
1 (1.5) 1 (1.5) 0 (0.0) 4 (1.2)
3 (4.6) 0 (0.0) 0 (0.0) 4 (1.2)
Table 5 Pharmacokinetics of AZD3199
Variable Dose group n G meana CVb
Cmax (nmol/L) 200 μg 53 1.136 118.5
400 μg 64 1.882 190.1
800 μg 59 4.011 107.0
AUC0-24 (nmol*h/L) 200 μg 53 4.91 99.5
400 μg 64 8.75 138.7
800 μg 59 14.85 107.1
aGeometric mean; bCoefficient of variation.
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healthy volunteers in the MAD study, the highest dose
in this study was chosen as 800 μg.
All doses of AZD3199 produced effective bronchodila-
tion with 24-hour duration of action that was compar-
able to, or greater than, that achieved with formoterol
twice-daily. However, no clear dose–response was ob-
served for the bronchodilatory effects of AZD3199 at ei-
ther peak or trough effects. Due to the lack of a clear
dose–response, the present study was unable to identify
a definitive dose of AZD3199 to carry forward to Phase
III investigation. The current data suggest that in COPD
patients a plateau of the dose–response curve may have
been reached at or below a once-daily dose of AZD3199
200 μg. The effects of AZD3199 at steady state may be
enhanced in patients with COPD relative to single doses,
resulting in lower doses being sufficient to achieve a
maximal bronchodilator response. Doses of AZD3199 at
less than 200 μg may therefore be sufficient to maintain
bronchodilation over 24 hours in patients with COPD.
A reduction in COPD symptom scores was seen after
AZD3199 800 μg and a reduction in the daily use of re-
liever medication was seen after all doses of AZD3199,
in comparison with placebo. Although the present study
was not powered to look at improvements in patient-
reported outcomes, some evidence of positive effects on
these variables was observed. CCQ scores were reduced
with AZD3199 200 μg, providing support for the use of
this dose in Phase III investigation. SGRQ-C scores were
also improved, complementing the bronchodilating ef-
fect achieved. It has been suggested that regular admi-
nistration of LABAs can lead to the development of
tolerance to the effects of bronchodilation, potentially
reducing the response to reliever medications such as
salbutamol. Tolerance did not appear to develop to
AZD3199 or formoterol in this 4-week study, as
there was no adverse effect on the post-salbutamol
FEV1 levels.
The incidence of adverse effects was generally low and
similar between study groups, and most adverse effects
were of mild intensity. There were few cases of post-
inhalation cough in the present study, but somewhat
more cases with AZD3199 400 μg and 800 μg. Therewere no clinically significant adverse findings for vital
signs, laboratory parameters and ECGs; AZD3199 was
therefore considered to be well-tolerated and no safety
concerns were raised. A limitation of this study was that
the relatively short 4-week duration of the study pre-
cluded examination of longer term safety and tolerability
parameters, but these can be assessed in future studies.
Four weeks is generally considered adequate for assess-
ments of efficacy and dose response.
Analysis of plasma AZD3199 revealed dose-proportional
pharmacokinetics. However, systemic exposure to
AZD3199 in patients with COPD was approximately
half of that previously reported in healthy volunteers
and patients with mild-to-moderate asthma, which
may be related to reduced absorption or increased
drug metabolism. This effect is in line with previous
studies demonstrating reduced systemic exposure to
formoterol, budesonide and fluticasone in patients
with COPD, compared with healthy volunteers [10].
Conclusions
All of the AZD3199 doses produced 24-hour broncho-
dilation, but with no clear dose–response, suggesting
that doses of 200 μg or less may be sufficient to main-
tain bronchodilation over 24 hours in patients with
COPD. No safety concerns were identified. Further
studies are required to determine the appropriate once-
daily AZD3199 dose for COPD.
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